AA
ANIK icon

AlphaMark Advisors’s Anika Therapeutics ANIK Stock Holding History

AlphaMark Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3
Closed – – 497
2017
Q2 		$0 Hold
3
– – ﹤0.01% 535
2017
Q1 		$0 Hold
3
– – ﹤0.01% 488
2016
Q4 		$0 Buy
+3
New +$139 ﹤0.01% 456

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

AlphaMark Advisors's ANIK Position: Q3 2017 in Review

AlphaMark Advisors sold out of Anika Therapeutics (ANIK) in Q3 2017, closing a stake of 3 shares.

AlphaMark Advisors first reported a position in ANIK in Q4 2016 and held it in 3 quarters. The position peaked at $0 in Q2 2017. 166 funds tracked by Wall St. Rank hold ANIK as of Q3 2017.

  • AlphaMark Advisors reported no remaining Anika Therapeutics position as of Q3 2017 after selling out during the quarter.
  • AlphaMark Advisors sold 3 Anika Therapeutics shares in Q3 2017.
  • AlphaMark Advisors first reported a position in Anika Therapeutics in Q4 2016 and held it in 3 quarters.
  • AlphaMark Advisors's Anika Therapeutics position peaked at $0 in Q2 2017.
  • 166 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2017.

Based on AlphaMark Advisors's 13F filing for Q3 2017, filed 2 Nov 2017.